Agios Pharmaceuticals, Inc.
AGIONext catalyst
AG-120
Chondrosarcoma
Get an email about AGIO's next catalysts
Track Agios Pharmaceuticals (AGIO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
2 upcoming, 1 past
FDA PDUFA Date mitapivat (sickle cell disease)
For Sickle cell disease. sNDA, accelerated approval, Priority Review. Verified against the company announcement on 2026-10-16.
Date changed: 2026-11-01 → 2027-02-01. New PDUFA goal date of February 1, 2027 for the mitapivat sNDA in sickle cell disease; company states it is launch-ready and in labeling discussions with FDA.
SourceAG-120 Phase 2 Est. Readout
Estimated primary completion for AG-120 trial (NCT04278781) in Chondrosarcoma. Topline data typically follows completion by weeks to months.
SourceHow AGIO's past catalysts played out
Market Overview
Stock performance and key metrics
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.: Table 1
WebsiteMitapivat
Sickle Cell Disease
AG-348
Pyruvate Kinase Deficiency
Tebapivat
Myelodysplastic Syndromes
Enasidenib
Hematologic Neoplasms
AG-120
Chondrosarcoma
ivosidenib and nivolumab
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mitapivat | Phase 3 | Sickle Cell Disease | - | - |
AG-348 | Phase 3 | Pyruvate Kinase Deficiency | - | - |
Tebapivat | Phase 2 | Myelodysplastic Syndromes | - | - |
Enasidenib | Phase 2 | Hematologic Neoplasms | - | - |
AG-120 | Phase 2 | Chondrosarcoma | - | - |
ivosidenib and nivolumab | Phase 2 | Advanced Solid Tumor | - | - |
Sickle Cell Disease
4 drugs in this indication
Pyruvate Kinase Deficiency
2 drugs in this indication
Myelodysplastic Syndromes
1 drug in this indication
Non-Transfusion-dependent Alpha-Thalassemia
1 drug in this indication
Pediatric Pyruvate Kinase Deficiency
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Agios Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Agios Pharmaceuticals, Inc.'s (AGIO) pipeline across Phase 3, Phase 2. Its lead program is Mitapivat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Agios Pharmaceuticals, Inc.'s next FDA catalyst?→
Agios Pharmaceuticals, Inc.'s (AGIO) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AGIO biotech catalysts?→
Add AGIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Agios Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
